Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation has recently completed a Phase 1 ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

Incyte (NASDAQ:INCY) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.In the table below, you'll find a summary of their recent ...

Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi ...

Incyte has launched the Vitiligo Innovators Program to honor exceptional individuals who have made significant contributions to the vitiligo community, according to a company press release. Noted ...

Incyte, itching for a piece of Dupixent's market, hits goals in midphase skin disease trial By Nick Paul Taylor Mar 11, 2024 7:16am Incyte clinical trial data JAK inhibitors Dermatology ...

Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry ’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame. The ...